Article |
By Alice Harrison and Stuart Jamieson,Lonza
In this article, Stuart Jamieson and Alice Harrison at Lonza discuss the downstream issues that development scientists encounter and the need for rapid method development.
White Paper |
By Mariana Breña, Christopher Parker, and Michael Mrvos,Cambrex
Cleaning procedures designed specifically to destroy microbial contaminants that may be present are an important component of any microbial control strategy.
Application Note |
By Dr. David K. Lyon, Ph.D.,Lonza
Bioavailability challenges are among the toughest problems faced by today’s formulators. This paper presents an overview of obstacles to bioavailability and summarizes the Lonza technology selection process.
Combination therapies delivered directly to the lung by dry powder inhalants are an effective means of reducing patient burden and improving care. Explore case studies illustrating the potential for improving care for critically ill patients.
It is critical to understand the significant competitive advantages of FDC products and the difficulties and potential pitfalls associated with their development and manufacturing in oral solid dosage forms.
A pharmaceutical producer was able to increase their compound library by 55% and reduce costs to maintain this increased library by more than 50% by streamlining their chemical compound collection processes.
SPR technology provides robust results from difficult samples. Explore how 90% of responders are satisfied with the robustness and reproducibility of our systems.
Review the problems, risks, and pain points that drug developers experience the most and explore the benefits of an integrated products and services platform for cell line development.
September 29, 2022 | 11:00 a.m. Eastern Daylight Time
In this upcoming webinar, experts from Lonza will discuss the process Lonza uses to develop a spray dried powder formulation and scale from early feasibility studies to commercial manufacturing. The webinar will focus on developments to enable processing of extremely poorly soluble molecules into drug-polymer amorphous dispersions for oral bioavailability enhancement.
